Erin McElvania, PhD., D(ABMM)
Dr. McElvania is currently the Director of Clinical Microbiology at Endeavor Health and a Clinical Professor of Pathology at the University of Chicago Pritzker School of Medicine. In addition to her clinical duties, she directs the Infectious Disease Diagnostics Research Laboratory which evaluates new instruments and assays for infectious disease testing. Dr. McElvania is active in the American Society for Microbiology and has served as branch president of the Illinois Society for Microbiology. She is an Editor for the Journal of Clinical Microbiology and is committed to enhancing the practice of clinical microbiology through research, with over 60 peer-reviewed publications. Her research interests include implementation and optimization of laboratory automation, digital pathology, and rapid pathogen identification.Dr. McElvania is currently the Director of Clinical Microbiology at Endeavor Health and a Clinical Professor of Pathology at the University of Chicago Pritzker School of Medicine. In addition to her clinical duties, she directs the Infectious Disease Diagnostics Research Laboratory which evaluates new instruments and assays for infectious disease testing. Dr. McElvania is active in the American Society for Microbiology and has served as branch president of the Illinois Society for Microbiology. She is an Editor for the Journal of Clinical Microbiology and is committed to enhancing the practice of clinical microbiology through research, with over 60 peer-reviewed publications. Her research interests include implementation and optimization of laboratory automation, digital pathology, and rapid pathogen identification.
Financial relationships
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:Becton Dickinson and Co.Topic:Laboratory automationDate added:07/07/2026Date updated:07/07/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:bioMerieuxTopic:Laboratory automationDate added:07/07/2026Date updated:07/07/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:Roche DiagnosticsTopic:Infectious disease diagnosticsDate added:07/07/2026Date updated:07/07/2026
-
Attribution:SelfType of financial relationship:AdvisorIneligible company:Shionogi and Co.Topic:Antimicrobial susceptibility testing methodsDate added:07/07/2026Date updated:07/07/2026
-
Attribution:SelfType of financial relationship:SpeakerIneligible company:Becton Dickinson and Co.Topic:Laboratory automationDate added:07/07/2026Date updated:07/07/2026
-
Attribution:SelfType of financial relationship:SpeakerIneligible company:CepheidTopic:Infectious disease diagnosticsDate added:07/07/2026Date updated:07/07/2026
-
Attribution:SelfType of financial relationship:SpeakerIneligible company:Roche DiagnosticsTopic:Infectious disease diagnosticsDate added:07/07/2026Date updated:07/07/2026
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:Abbott Molecular Inc.Topic:New diagnostic assays or devicesDate added:07/07/2026Date updated:07/07/2026
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:Becton Dickinson and Co.Topic:New diagnostic assays or devicesDate added:07/07/2026Date updated:07/07/2026
-
Attribution:SelfType of financial relationship:ResearcherIneligible company:CepheidTopic:New diagnostic assays or devicesDate added:07/07/2026Date updated:07/07/2026

Facebook
X
LinkedIn
Forward